Dr. Sella Brosh is the Co-Founder and CEO of NVision Imaging Technologies, a quantum-powered medical imaging company pioneering metabolic MRI to transform early cancer treatment assessment.

Dr. Brosh holds an M.D. from Tel Aviv University and served as a combat engineering officer before building a career in healthcare strategy at McKinsey and Company and Oscar Health.

A passionate advocate for applied quantum in medicine, Dr. Brosh has spoken at leading quantum computing forums including the Convergence Quantum conference in Cambridge, MA, on precision oncology.

Prior to NVision, Dr. Brosh led global commercialization efforts in pharma and medical devices at McKinsey's US Mid-Atlantic office, working alongside R&D and Market Access teams at top-10 industry players.

Under his leadership since 2016, NVision has raised over $35M in private funding including a $30M Series A led by Playground Global, plus more than 35M euros in European public grants, and secured partnerships with institutions such as Memorial Sloan Kettering and the University of Cambridge.